MeiraGTx Holdings (MGTX) Share-based Compensation (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Share-based Compensation came in at $5.6 million in Q4 2025, down 75.65% YoY from $22.9 million in Q4 2024, and up 18.4% on a QoQ basis from $4.7 million in Q3 2025.
MeiraGTx Holdings (MGTX) Share-based Compensation (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Share-based Compensation data on file, last reported at $5.6 million in Q4 2025.
- Quarterly Share-based Compensation fell 75.65% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.2 million (down 8.72% YoY) and the FY2025 annual result came in at $24.7 million, down 1.95% from the prior year.
- Share-based Compensation improved to $5.6 million in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $22.9 million in Q4 2024 to a low of $2.1 million in Q1 2025.
- A 5-year average of $6.6 million and a median of $5.7 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 42.83% — and 2025, when it sank 75.65%.
- Tracing MGTX's Share-based Compensation over 5 years: stood at $7.1 million in 2021, then dropped by 4.61% to $6.8 million in 2022, then slipped by 0.59% to $6.8 million in 2023, then jumped by 237.78% to $22.9 million in 2024, then slumped by 75.65% to $5.6 million in 2025.
- The last three Share-based Compensation figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - | 5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.57 Mn |
| Dec 31, 2025 | 5.57 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 22.85 Mn |
| Dec 31, 2024 | 22.85 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 5.81 Mn |
| Jun 30, 2024 | 5.81 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Sep 30, 2023 | 6.77 Mn |
| Sep 30, 2023 | 6.77 Mn |
| Jun 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | 7.27 Mn |